Bupropion hydrochloride (HCl) is an antidepressant that has many different biological targets, acting as both a norepinephrine-dopamine reuptake inhibitor as well as a nicotinic antagonist. This second-generation antidepressant is available in 3 bioequivalent formulations: immediate release, sustained release, and extended release, allowing providers to customize a patient's regimen for maximum tolerability and compliance. Although bupropion HCl's safety and tolerability have been demonstrated through several clinical trials, there are still a number of adverse effects that have been reported in the literature. These include headache, agitation, tremor, and insomnia. There is also an increased risk of developing seizures during bupropion treatment. Although urinary symptoms were noted during the clinical trials, these are relatively rare adverse effects. Here we report the case of a 61-year-old man who developed diurnal enuresis during treatment with bupropion HCl sustained release. We will review the adverse effect burden associated with the use of bupropion and discuss the neuropharmacology of urinary symptoms associated with antidepressant treatment.
*Department of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine, University of South Florida, Tampa
†Department of Psychiatry, College of Medicine, University of Florida, Gainesville
‡Mental Health and Behavioral Sciences Service, James A. Haley Veterans Hospital, Tampa, FL.
Address correspondence and reprint requests to Anjali Nirmalani-Gandhy, MD, Mental Health and Behavioral Sciences Service, James A. Haley Veterans Hospital, 13000 Bruce B. Downs Blvd, 116A Tampa, FL 33612; E-mail: email@example.com
Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.
Online date: October 22, 2019